HOLEE SHIZZLES‼️ 🚨 BREAKING: Internal Records show Johnson & Johnson Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ For Autism Risk In 2018, and doctors were warning J&J as early as 2008 • According to the DCNF report, J&J's Janssen division (its pharmaceutical arm) began fielding queries from consumers and doctors about a potential acetaminophen-autism link as early as 2008. Key highlights from the emails: - 2008: J&J's Office of Consumer Medical Safety Lead, Andre Mann, received a physician's letter raising concerns. He wrote internally: "Not much choice but to consider this a safety signal that needs to be evaluated." - 2012: Leslie Shur, head of J&J's post-market drug safety monitoring, got an alert from a worried father about the risks. A colleague flagged it as urgent "in case this goes to press." - 2018: Rachel Weinstein, U.S. director of epidemiology for Janssen, emailed colleagues: "The weight of the EVIDENCE is starting to feel heavy to me" regarding associations between prenatal acetaminophen use and neurodevelopmental disorders like AUTISM. These weren't just casual notes—J&J was ACTIVELY MONITORING studies and parent reports but FAILED to publicly disclose them. The company spun off its consumer health unit (including Tylenol) to Kenvue in 2023, shifting liabilities. This revelation is fueling lawsuits: A multi-district litigation (MDL) in New Jersey federal court is probing whether manufacturers failed to warn about risks RIGHT NOW.

CitizensColumn Based on your tweets emphasizing crypto freedom, DeFi for financial independence, excitement for market corrections, and agreement with critiques of lacking critical thinking in modern discourse, you fall at 78 on the scale—firmly right-leaning with libertarian economic and anti-establishment views.